Healthy Subjects
Conditions
Keywords
levamlodipine, bioequivalence, pharmacokinetics
Brief summary
The single-dose randomized, open-label, two-period crossover study was executed in the Phase I Clinical Research Center of the Affiliated Hospital of Qingdao University. According to the random table generate by SAS 9.4, the subjects were divided into two groups at the ratio of 1:1. The select qualified volunteers were hospitalized in the Phase I Clinical Research Center, and fasted for 10 hours overnight until administration. The medicine was swallowed with 240 ml water at room temperature. Blood samples were taken before administration and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 24, 36, 48, 72, 96, 120, 144, 168 hours after administration. The samples were centrifuged at 1,800 g for 10 min at 4 °C to separate the plasma. The plasma samples were divided into two aliquots and stored at -80 °C until bioanalysis. The half-life of levamlodipine is 30 \ 50 hours. Washout period, the interval between two administration, is 21 days. In the two periods, the operation was kept the same. Moreover, in high fat meal group, the high-fat breakfast was arranged within half an hour before taking the medicine. Other procedures were the same as those in the fasting group.
Interventions
DRUGAmlodipine 10 mg
The subjects randomly received single oral administration of amlodipine 10 mg.
DRUGLevamlodipine 5 mg
The subjects randomly received single oral administration of levamlodipine 5 mg.
Sponsors
The Affiliated Hospital of Qingdao University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
19 Years to 48 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male or female aged 18 and above. * The body mass index is in the range of 18.6-28.5 kg/m2 (including the critical value). The weight of male is not less than 50.0 kg, and that of female is not less than 45.0 kg. * The following examination show that the indicators are normal or abnormal without clinical significance. The examination including: Vital signs, physical examination, blood routine, blood biochemistry, urinalysis, pregnancy test for female, serological tests for hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), and syphilis virus, 12 lead ECG, breath test for alcohol, drug abuse test. * The subjects have no family planning within 3 months and could select contraceptive method. * Before the study, all subjects have been informed of the study's purpose, protocal, benefits, and risks, and signed the informed consent voluntarily.
Exclusion criteria
* Being allergy to the study medications, smoking, alcohol abuse. * Participation in another clinical trial within 3 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Peak Plasma Concentration (Cmax) | 64 days | Evaluation of Peak Plasma Concentration (Cmax) |
| Area under the plasma concentration versus time curve (AUC)0-t | 64 days | Evaluation of Area under the plasma concentration versus time curve (AUC)0-t |
| Area under the plasma concentration versus time curve (AUC)0-∞ | 64 days | Evaluation of Area under the plasma concentration versus time curve (AUC)0-∞ |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of abnormal pulse | 64 days | Temperature the pulse |
| Incidence of Treatment-Emergent Adverse Events | 64 days | Collection of adverse events |
| Incidence of abnormal electrocardiogram waveform | 64 days | Electrocardiogram inspection |
| Incidence of abnormal blood pressure | 64 days | Monitor both systolic and diastolic blood pressure |
| Incidence of abnormal temperature | 64 days | Monitor the temperature |
Countries
China
Outcome results
None listed